Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Trastuzumab Deruxtecan (DS-8201) in Patients With HER2-Expressing Metastatic Colorectal Cancer (DESTINY-CRC01): A Multicentre, Open-Label, Phase 2 Trial
Lancet Oncol 2021 May 04;[EPub Ahead of Print], S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, H Kawakami, K Yamaguchi, T Nishina, M Fakih, E Elez, J Rodriguez, F Ciardiello, Y Komatsu, T Esaki, K Chung, Z Wainberg, A Sartore-Bianchi, K Saxena, E Yamamoto, E Bako, Y Okuda, J Shahidi, A Grothey, T YoshinoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.